(Q34029593)

English

Evidence-based recommendations for the therapeutic management of angioedema owing to hereditary C1 inhibitor deficiency: consensus report of an International Working Group

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

Evidence-based recommendations for the therapeutic management of angioedema owing to hereditary C1 inhibitor deficiency: consensus report of an International Working Group (English)

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

C1 inhibitor deficiency

1 reference

based on heuristic

inferred from title

object named as

B Zuraw

8

0 references

Teresa Caballero

object named as

T Caballero

3

0 references

author name string

M Cicardi

1

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

K Bork

2

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

T Craig

4

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

H H Li

5

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

H Longhurst

6

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

A Reshef

7

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

HAWK (Hereditary Angioedema International Working Group)

9

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

publication date

30 November 2011

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

67

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

2

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

147-157

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

Clinical practice. Hereditary angioedema

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2011.02751.X

21 January 2018

The burden of hospitalizations and emergency department visits with hereditary angioedema and angioedema in the United States, 2007.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2011.02751.X

21 January 2018

Hereditary and acquired angioedema: problems and progress: proceedings of the third C1 esterase inhibitor deficiency workshop and beyond

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2011.02751.X

21 January 2018

2010 International consensus algorithm for the diagnosis, therapy and management of hereditary angioedema

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2011.02751.X

21 January 2018

Canadian 2003 International Consensus Algorithm For the Diagnosis, Therapy, and Management of Hereditary Angioedema.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2011.02751.X

21 January 2018

C1 inhibitor deficiency: consensus document

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2011.02751.X

21 January 2018

Nanofiltered C1 inhibitor concentrate for treatment of hereditary angioedema

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2011.02751.X

21 January 2018

Recombinant human C1-inhibitor for the treatment of acute angioedema attacks in patients with hereditary angioedema.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2011.02751.X

21 January 2018

Icatibant, a new bradykinin-receptor antagonist, in hereditary angioedema

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2011.02751.X

21 January 2018

Efficacy of human C1 esterase inhibitor concentrate compared with placebo in acute hereditary angioedema attacks

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2011.02751.X

21 January 2018

Treatment of hereditary angioedema with danazol. Reversal of clinical and biochemical abnormalities

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2011.02751.X

21 January 2018

Methyltestosterone Therapy in Hereditary Angioedema

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2011.02751.X

21 January 2018

Treatment of hereditary angioedema with a vapor-heated C1 inhibitor concentrate

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2011.02751.X

21 January 2018

Long-term treatment of hereditary angioedema with attenuated androgens: a survey of a 13-year experience

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2011.02751.X

21 January 2018

Benefits and risks of danazol in hereditary angioedema: a long-term survey of 118 patients

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2011.02751.X

21 January 2018

Long-term efficacy of danazol treatment in hereditary angioedema.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2011.02751.X

21 January 2018

Appraisal of danazol prophylaxis for hereditary angioedema

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2011.02751.X

21 January 2018

Hepatocellular adenomas in patients taking danazol for hereditary angio-oedema

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2011.02751.X

21 January 2018

Danazol-induced hepatocellular adenoma in patients with hereditary angio-oedema

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2011.02751.X

21 January 2018

Danazol therapy: an unusual aetiology of hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2011.02751.X

21 January 2018

Adverse effects of danazol prophylaxis on the lipid profiles of patients with hereditary angioedema.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2011.02751.X

21 January 2018

Long-term danazol prophylaxis does not lead to increased carotid intima-media thickness in hereditary angioedema patients.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2011.02751.X

21 January 2018

Effects of short-term and long-term danazol treatment on lipoproteins, coagulation, and progression of atherosclerosis: two clinical trials in healthy volunteers and patients with hereditary angioedema.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2011.02751.X

21 January 2018

Hereditary angioedema: Safety of long-term stanozolol therapy.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2011.02751.X

21 January 2018

Long-term prophylaxis with C1-inhibitor (C1 INH) concentrate in patients with recurrent angioedema caused by hereditary and acquired C1-inhibitor deficiency

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2011.02751.X

21 January 2018

Self-administration of C1-inhibitor concentrate in patients with hereditary or acquired angioedema caused by C1-inhibitor deficiency

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2011.02751.X

21 January 2018

C1-inhibitor concentrate for individual replacement therapy in patients with severe hereditary angioedema refractory to danazol prophylaxis.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2011.02751.X

21 January 2018

A randomized, controlled trial to study the efficacy and safety of C1 inhibitor concentrate in treating hereditary angioedema

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2011.02751.X

21 January 2018

Prospective study of C1 esterase inhibitor in the treatment of successive acute abdominal and facial hereditary angioedema attacks

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2011.02751.X

21 January 2018

Treatment with C1 inhibitor concentrate in abdominal pain attacks of patients with hereditary angioedema

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2011.02751.X

21 January 2018

Treatment of 193 episodes of laryngeal edema with C1 inhibitor concentrate in patients with hereditary angioedema

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2011.02751.X

21 January 2018

Management of hereditary angioedema in pediatric patients.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2011.02751.X

21 January 2018

The natural history of hereditary angioedema and the impact of treatment with human C1-inhibitor concentrate during pregnancy: a long-term survey.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2011.02751.X

21 January 2018

The effect of long-term danazol prophylaxis on liver function in hereditary angioedema-a longitudinal study

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2011.02751.X

21 January 2018

Hereditary angio-oedema in children: a management guideline.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2011.02751.X

21 January 2018

Treatment of skin swellings with C1-inhibitor concentrate in patients with hereditary angio-oedema

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2011.02751.X

21 January 2018

The use of plasma-derived C1 inhibitor in the treatment of hereditary angioedema

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2011.02751.X

21 January 2018

Safety and efficacy of pasteurized C1 inhibitor concentrate (Berinert P) in hereditary angioedema: a review. jean.de.serres@aventis.com

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2011.02751.X

21 January 2018

Reduction in transmission of hepatitis C after the introduction of a heat-treatment step in the production of C1-inhibitor concentrate.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2011.02751.X

21 January 2018

Treatment with C1-inhibitor concentrate does not induce IgM type anti-C1 inhibitor antibodies in patients with hereditary angioedema

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2011.02751.X

21 January 2018

Ecallantide (DX-88), a plasma kallikrein inhibitor for the treatment of hereditary angioedema and the prevention of blood loss in on-pump cardiothoracic surgery

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2011.02751.X

21 January 2018

Critical role of kallikrein in hereditary angioedema pathogenesis: a clinical trial of ecallantide, a novel kallikrein inhibitor

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2011.02751.X

21 January 2018

Response time for ecallantide treatment of acute hereditary angioedema attacks

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2011.02751.X

21 January 2018

Treatment of acute edema attacks in hereditary angioedema with a bradykinin receptor-2 antagonist (Icatibant).

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2011.02751.X

21 January 2018

Management of acute attacks of hereditary angioedema: potential role of icatibant

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2011.02751.X

21 January 2018

HAE international home therapy consensus document.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2011.02751.X

21 January 2018

What kind of evidence is it that Evidence-Based Medicine advocates want health care providers and consumers to pay attention to?

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2011.02751.X

21 January 2018

The role of evidence-based medicine and clinical trials in rare genetic disorders

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2011.02751.X

21 January 2018

Grading quality of evidence and strength of recommendations

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2011.02751.X

21 January 2018

Identifiers

10.1111/J.1398-9995.2011.02751.X

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q34029593&oldid=1954683124"